Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia

Grants

Funding Acknowledgements

[ "This research was undertaken in part using the MX2 beamline at the Australian Synchrotron, part of the Australian Nuclear Science and Technology Organisation (ANSTO), and made use of the Australian Cancer Research Foundation (ACRF) detector. We thank the beamline staff for their assistance, particularly Dr. Santosh Panjikar for his help with data processing. We thank Anna Sapa for technical assistance, Tony Cambareri for the 1B5 hybridoma, and Nic Nicola, Frank Stomski, and Amanda Mitchell for helpful discussions. We thank the South Australian Cancer Research Biobank (Adelaide, Australia), the Leukemia Tissue Bank at Princess Margaret Cancer Centre (Toronto, Ontario, Canada), and particularly Mark D. Minden, Andrea Arruda, and Amanda Mitchell for providing access to primary AML patient samples. We acknowledge the use of the CSIRO Collaborative Crystallization Centre (Melbourne, Australia) for our initial crystallization studies, the ACRF Rational Drug Discovery Centre (Fitzroy, Australia), and the ACRF Facility of Innovative Cancer Drug Discovery (Parkville, Australia). We also acknowledge the use of the ACRF Cancer Genomics Facility (J. Toubia) (Adelaide, Australia), the ACRF Cancer Discovery Accelerator Facility (Adelaide, Australia), and the Cytometry Facility at the Centre for Cancer Biology (Adelaide, Australia). We thank the ACRF (Cancer Discovery Accelerator) for funding the imaging equipment used in this work. We thank Arthi Macpherson from the Victorian Centre for Functional Genomics and the ACRF Translational Reverse Phase Protein Array platform at Peter MacCallum Cancer Centre for assistance with RPPA. This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC) to A.F. Lopez, M.W. Parker, and T. Hughes (APP1071897); to A.F. Lopez, D. Tvorogov, and D. Thomas (APP1182564); to A.F. Lopez, W.L. Kan, R.J. D & apos;Andrea, S.E. Samaraweera, J.E. Dick, D. Ross, and C.G. Begley (APP2021560); Cancer Council SA Beat Cancer Fund to T.R. Hercus and A.F. Lopez (APP1148221); Cancer Council Victoria to U. Dhagat, S.E. Broughton, M.W. Parker, and L. Purton (APP1123401); Cure Cancer Australia to S.E. Broughton (APP1098567); and ACRF to M.W. Parker. Funding from the Victorian Government Operational Infrastructure Support Scheme to St Vincent & apos;s Institute is acknowledged. S.E. Broughton was supported by a Leukemia Foundation Fellowship, and M.W. Parker is an NHMRC Research Fellow (APP1117183) and an NHMRC Investigator (APP1194263). The Victorian Centre for Functional Genomics (K.J. Simpson) is funded by the ACRF, the Australian Phenomics Network through funding from the Australian Government & apos;s National Collaborative Research Infrastructure Strategy program, the Peter MacCallum Cancer Centre Foundation, and the University of Melbourne Research Collaborative Infrastructure Program. J.E. Dick is supported by funds from the Princess Margaret Cancer Centre Foundation, Ontario Institute for Cancer Research through funding provided by the Government of Ontario, Canadian Institutes for Health Research grants 130412, 89932, and 154293, International Development Research Centre Ottawa Canada grants 108401 and 109153, Canadian Cancer Society grant 703212, Terry Fox New Frontiers Program Project Grant 1047, the University of Toronto & apos;s Medicine by Design initiative with funding from the Canada First Research Excellence Fund, and a Canada Research Chair.r The publication costs of this article were defrayed in part by the payment of publication fees.", "Therefore, and solely to indicate this fact, this article is hereby marked \"advertisement\" in accordance with 18 USC section 1734." ]